JP6666053B2 - Iald産生促進剤 - Google Patents
Iald産生促進剤 Download PDFInfo
- Publication number
- JP6666053B2 JP6666053B2 JP2015071248A JP2015071248A JP6666053B2 JP 6666053 B2 JP6666053 B2 JP 6666053B2 JP 2015071248 A JP2015071248 A JP 2015071248A JP 2015071248 A JP2015071248 A JP 2015071248A JP 6666053 B2 JP6666053 B2 JP 6666053B2
- Authority
- JP
- Japan
- Prior art keywords
- iald
- bifidobacterium
- production
- production promoter
- bacterium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 24
- 239000004480 active ingredient Substances 0.000 claims description 11
- 241001608472 Bifidobacterium longum Species 0.000 claims description 10
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 9
- 241000894006 Bacteria Species 0.000 description 20
- 241000186000 Bifidobacterium Species 0.000 description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 102100030703 Interleukin-22 Human genes 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 108010074109 interleukin-22 Proteins 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 5
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 5
- OLNJUISKUQQNIM-UHFFFAOYSA-N indole-3-carbaldehyde Chemical compound C1=CC=C2C(C=O)=CNC2=C1 OLNJUISKUQQNIM-UHFFFAOYSA-N 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 241000186014 Bifidobacterium angulatum Species 0.000 description 2
- 241000186011 Bifidobacterium catenulatum Species 0.000 description 2
- 239000012901 Milli-Q water Substances 0.000 description 2
- 102000015728 Mucins Human genes 0.000 description 2
- 108010063954 Mucins Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 1
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 1
- 102000003984 Aryl Hydrocarbon Receptors Human genes 0.000 description 1
- 108090000448 Aryl Hydrocarbon Receptors Proteins 0.000 description 1
- 241001134770 Bifidobacterium animalis Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 241000186148 Bifidobacterium pseudolongum Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- HWXBTNAVRSUOJR-UHFFFAOYSA-N alpha-hydroxyglutaric acid Natural products OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 description 1
- 229940009533 alpha-ketoglutaric acid Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940118852 bifidobacterium animalis Drugs 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 229940004120 bifidobacterium infantis Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
すなわち、本発明は以下の構成からなる。
(1)ビフィドバクテリウム属の菌を有効成分とする、IALD産生促進剤。
(2)ビフィドバクテリウム属の菌がビフィドバクテリウム・ロンガムの菌である、上記(1)に記載のIALD産生促進剤。
(3)ビフィドバクテリウム属の菌がSBT−2928(FERM P−10657)である、上記(1)に記載のIALD産生促進剤。
1.1.菌体の準備
表1に示した乳酸菌11株及びビフィドバクテリウム属の菌12株を供試菌として使用した。乳酸菌はMRS液体培地にて、ビフィドバクテリウム属の菌はGAM液体培地にて37℃,16時間静置培養した。各菌体を遠心分離(1,912×g,4℃,10min)にて回収し、1mM MgSO4を含有する100mM リン酸カリウム緩衝液(pH7、以下、緩衝液と呼ぶ)を用いて3回洗浄した。
反応は休止菌体系にて実施した。表1に示したように、菌体懸濁液を供試菌によってO.D.600=3.7〜7.9に調整して、次のA、Bの2つの反応液組成にて37℃で18時間、反応を行った。
反応液組成A:20mM トリプトファン
反応液組成B:20mM トリプトファン and 20mM α−ケトグルタル酸
反応液は遠心分離後(9,100×g,4℃,10min)、上清を回収し、フィルター(0.22μm)にて不溶物を除去したものをHPLC分析サンプルとした。分析はAgilent社の1200シリーズを使用した。溶離液A(95% Milli−Q water,5% Acetonitrile(ACN),0.05% Trifluoroacetic acid(TFA))で平衡化したODSカラム(Hydrosphere C18 粒子径(μm)S−5,細孔径 4.6X250,品番 HS12S05−2546WT,メーカー YMC)に分析サンプルを10μlインジェクトし、流速1ml/minとして溶離液B(5% Milli−Q water,95% ACN,0.05% TFA)の濃度勾配(%B(time):10(0)→50(16)→50(16)→100(16.1)→100(20)→10(20.1)→10(26))により行った。カラムオーブンは40℃とした。分光光度計にてIALDの吸収波長の試験を行った結果、IALDの検出は300nmにおける吸収を利用した。ここで、合成活性(Synthesizing activity)を、反応により生成したIALD合成量(Concentration. ppm)を供試菌のO.D.600の値で割った値と定義する(式1)。
図1、図2より、α−ケトグルタル酸の有無に関わらず、ラクトバチルス属(Lactobacillus)と比較して、ビフィドバクテリウム属の菌(Bifidobacterium属)、特にビフィドバクテリウム・ロンガム(Bifidobacterium longum)のIALD産生能が優れていることが確認できた。また、その中でも特にSBT−2928(FERM P−10657)の効果が大きい事が確認できた。従って、これらのビフィドバクテリウム属の菌を有効成分として、IALD産生促進剤が提供できることが示された。
Claims (1)
- ビフィドバクテリウム・ロンガムSBT−2928(FERM P−10657)を有効成分とするIALD産生促進剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015071248A JP6666053B2 (ja) | 2015-03-31 | 2015-03-31 | Iald産生促進剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015071248A JP6666053B2 (ja) | 2015-03-31 | 2015-03-31 | Iald産生促進剤 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019101049A Division JP6802323B2 (ja) | 2019-05-30 | 2019-05-30 | Iald産生促進剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016190804A JP2016190804A (ja) | 2016-11-10 |
JP6666053B2 true JP6666053B2 (ja) | 2020-03-13 |
Family
ID=57245712
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015071248A Active JP6666053B2 (ja) | 2015-03-31 | 2015-03-31 | Iald産生促進剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6666053B2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021035992A (ja) * | 2020-11-25 | 2021-03-04 | 雪印メグミルク株式会社 | Iald産生促進剤 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020164492A (ja) * | 2019-03-29 | 2020-10-08 | 森永乳業株式会社 | インドール乳酸化合物の製造方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007020884A1 (ja) * | 2005-08-12 | 2007-02-22 | Meiji Dairies Corporation | β-ディフェンシンを介した感染予防効果を有するビフィズス菌または乳酸菌とそれを含有する食品・医薬品組成物 |
CN102802648A (zh) * | 2009-05-11 | 2012-11-28 | 雀巢产品技术援助有限公司 | 约氏乳杆菌La1 NCC533(CNCM I-1225)和免疫病症 |
TWI572354B (zh) * | 2010-09-09 | 2017-03-01 | 明治股份有限公司 | 抑制發炎之組成物 |
-
2015
- 2015-03-31 JP JP2015071248A patent/JP6666053B2/ja active Active
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021035992A (ja) * | 2020-11-25 | 2021-03-04 | 雪印メグミルク株式会社 | Iald産生促進剤 |
JP7080296B2 (ja) | 2020-11-25 | 2022-06-03 | 雪印メグミルク株式会社 | Iald産生促進剤 |
Also Published As
Publication number | Publication date |
---|---|
JP2016190804A (ja) | 2016-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Balzaretti et al. | A novel rhamnose-rich hetero-exopolysaccharide isolated from Lactobacillus paracasei DG activates THP-1 human monocytic cells | |
Donnarumma et al. | Lactobacillus crispatus L1: high cell density cultivation and exopolysaccharide structure characterization to highlight potentially beneficial effects against vaginal pathogens | |
MX2022003374A (es) | Cepas bacterianas, sus composiciones y su uso para el tratamiento de trastornos gastrointestinales. | |
US11591416B2 (en) | Exopolysaccharides and uses thereof | |
CA2973223A1 (en) | Probiotic and prebiotic compositions, and methods of use thereof for modulation of the microbiome | |
Rodrigues da Cunha et al. | Characterization of Lactobacillus gasseri isolates from a breast-fed infant | |
MX2022003372A (es) | Cepas bacterianas, sus composiciones y su uso para el tratamiento de trastornos gastrointestinales. | |
WO2015147277A1 (ja) | 酪酸産生菌及びその利用 | |
Li et al. | In vitro and in vivo investigations of probiotic properties of lactic acid bacteria isolated from Chinese traditional sourdough | |
KR102248111B1 (ko) | 신규한 비피도박테리움 비피덤 균주 및 균주 유래 다당체 | |
Butorac et al. | The functional capacity of plantaricin-producing Lactobacillus plantarum SF9C and S-layer-carrying Lactobacillus brevis SF9B to withstand gastrointestinal transit | |
Fugaban et al. | Probiotic potential and safety assessment of bacteriocinogenic Enterococcus faecium strains with antibacterial activity against Listeria and vancomycin-resistant enterococci | |
JP6666053B2 (ja) | Iald産生促進剤 | |
WO2011125619A1 (ja) | 腸管保護剤 | |
van Bokhorst‐van de Veen et al. | Genotypic adaptations associated with prolonged persistence of Lactobacillus plantarum in the murine digestive tract | |
Yetiman et al. | Assessment of Genomic and Metabolic Characteristics of Cholesterol-Reducing and GABA Producer Limosilactobacillus fermentum AGA52 Isolated from Lactic Acid Fermented Shalgam Based on “In Silico” and “In Vitro” Approaches | |
JP6802323B2 (ja) | Iald産生促進剤 | |
JP7080296B2 (ja) | Iald産生促進剤 | |
US10092566B2 (en) | Composition for controlling a gut immunity and use thereof | |
Yılmaz-ersan et al. | Bifidojenik faktör olarak laktoz türevlerinin önemi | |
Mane et al. | Characterisation of colonisation properties of vaginal lactobacilli from healthy Indian women: Implications for identification of potential probiotic candidates | |
Stojanovski et al. | Utilization of xylooligosaccharides from different Lactobacillus strains | |
Park et al. | Physiological characteristics and production of folic acid of lactobacillus plantarum JA71 isolated from jeotgal, a traditional Korean fermented seafood | |
Lin et al. | Isolation and Characterisation of Probiotics for Antagonising Cariogenic Bacterium Streptococcus mutans and Preventing Biofilm Formation | |
Basumatary et al. | Isolation and exploration of potential probiotic attributes of a novel isolate Pedicoccus acidilactici CITKHZ7 obtained from traditional fermented fish paste Hentak |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180315 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190213 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190410 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190530 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190821 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190927 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191211 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200219 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200219 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6666053 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |